Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3 Targeted Fluorescence Imaging in HCC Surgery
NCT05047510Recruiting
- Sponsor
- Chinese Academy of Sciences
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-GPC3-IRDye800CW in hepatocellular carcinoma (HCC), sponsored by Chinese Academy of Sciences. Primary endpoint: HCC lesions. Started Sep 2021; status: recruiting.
02
Drugs
anti-GPC3-IRDye800CW
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05047510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047510.